Insiders / UBS Oncology Impact Fund L.P.
UBS Oncology Impact Fund L.P.
CIK 1691428personinsiderbeneficial owner
Companies
5
First seen
Jan 7, 2021
Last activity
Dec 4, 2025
Companies
| Company | Shares held | Latest |
|---|---|---|
| Cullinan Therapeutics, Inc. · CGEM | 7,913,887 | — |
| Tcr2 Therapeutics Inc. · TCRR | 0 | — |
| Harpoon Therapeutics, Inc. · HARP | — | — |
| ITeos Therapeutics, Inc. · ITOS | — | — |
| Werewolf Therapeutics, Inc. · HOWL | — | — |
All securities held
2 positions · latest reported per filing
Shares
| Company | Security | Shares |
|---|---|---|
| Cullinan Therapeutics, Inc. | Common stock | 7,913,887 |
Other
| Company | Security | Shares |
|---|---|---|
| Cullinan Therapeutics, Inc. | Unclassified | 7,648,268 |
Ownership percentages elsewhere on the site count common and ordinary shares only, because that is what shares outstanding are measured in. Everything above is a real holding; not all of it is a share of the company.
Activity
InsidersInstitutions
This person's trades in company stock, across every company.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Jan 12, 2021 | Buy Open-market buy | CGEM Cullinan Therapeutics, Inc. Common Stock | $6.30M | +300K +3.94% | 7,913,887 12.30% of shares | high |
| Aug 23, 2021 | Sell Open-market sale | CGEM Cullinan Therapeutics, Inc. Common Stock | $1.55M | -53K -0.67% | 7,858,018 12.21% of shares | medium |
| Aug 24, 2021 | Sell Open-market sale | CGEM Cullinan Therapeutics, Inc. |